<?xml version="1.0" encoding="UTF-8"?>
<p id="P92">
 <bold>Boceprevir.</bold> Boceprevir is a linear peptidomimetic ketoamide serine protease inhibitor that was recently approved for the treatment of CHC, particularly for genotype 1.
 <sup>
  <xref ref-type="bibr" rid="R194">194</xref>
 </sup> It is available in oral formulation, and the time to peak concentration after oral administration is 2 hours. Food enhances its absorption. Boceprevir is metabolized primarily in the liver. It has an elimination half-life of 3 hours and is excreted mostly in the feces.
 <sup>
  <xref ref-type="bibr" rid="R194">194</xref>
 </sup>
</p>
